I
INTEGRATED LABORATORY SYSTEMS INC.
Integrated Laboratory Systems, LLC is a contract research organization providing research and testing services to the pharmaceutical, chemical, agrochemical, food additive, and consumer product industries as well as to the Federal government. ILS conducts investigative toxicology, genetic toxicology, computational toxicology, histology, pathology, molecular biology, and information science services tailored to meet our clients' needs. ILS uses a flexible and comprehensive service model to provide a full suite of scientific services compliant with national and international regulatory requirements to ensure the highest quality products.
Country/Area ：United States
Company Email ：info@inotivco.com
Industry ：BiotechnologyIndustrial Services and AccessoriesBusiness ServicesPet SuppliesBusiness Services General
Company address ：PO Box 13501, Durham, North Carolina, 27709, United States
Company website ：*****
Company phone ：(919) 281-1110
Established ：1985
Company Revenue ：$21,626,000
Number of employees ：103
SIC Code ：80807
NAICS Code ：54541
Main Products ：Surgical ServicesVisit Our Virtual BoothCustom-cut Paper Cage LinersPhytoestrogen ReferencesMedical Device PathologyPathology andTargeted ProteomicsInfectious DiseaseEnrichment ProductsPre-Marketing AuthorizationResearch Model Support ServicesDiscovery Bioanalysis and BiomarkersGenetic Toxicology (GLP and Non-GLP)Inflammation and ImmunologyGenetic Testing ServicesGenetically Engineered Models and Services (GEMS)Metabolic and Diabetic DiseaseDrug Metabolism and Pharmacokinetics (DMPK) ( in vitro andin vivo )Predictive and Computational ToxicologyBioanalysis: Small Molecule (GLP)Custom Antibody Production ServicesCell Line ReferencesCustom Research DietsFull Spectrum Health MonitoringIn Vivo ToxicologyHealth Monitoring ReportsCell and Molecular BiologyExploratory ToxicologyContract Breeding ServicesDisease Pharmacology ( in vitro andin vivo )Histology and PathologyConcordat on OpennessShelf Life of Diets Used In ResearchIND-EnablingTumor Models and ServicesModels by Therapeutic AreaBioanalysis: Large Molecule (GLP)Development and Reproductive ToxicologyModel Sampling ProgramMedicated DietsEusoft Labs™ (LIMS)Biospecimen ServicesStandard Natural Ingredient DietsAccessibility StatementDo Not Sell Or Share My InformationDiet FAQsIn Vitro ToxicologyAnimal Welfare Statement
Company News
Inotiv, Inc. Announces Expansion of Safety Assessment Offerings with Acquisition of Integrated Laboratory Systems, LLC
Jan 10, 2022
WEST LAFAYETTE, Ind., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that the Company has completed the purchase of Integrated Laboratory Systems, LLC (“ILS”), a portfolio company of Sier Capital Partners (“Sier Capital”). ILS is a contract researc
Jan 10, 2022
Sier Capital Partners Announces Investment Supporting ILS GrowthSep 14, 2020
Sier Capital Partners is excited to announce it is supporting the management team of Integrated Laboratory Systems (ILS) in an acquisition of the company.
Sep 14, 2020Web Summary
Q1: What is the company name and its address?
A1: The company name is Integrated Laboratory Systems Inc., but unfortunately, the provided text does not explicitly mention the company's physical address.
Q2: What products and services does Inotiv Solutions offer for in vivo discovery and toxicology?
A2: Inotiv Solutions offers a wide range of products and services, including Discovery and Translational Sciences, Disease Pharmacology (in vitro and in vivo), Drug Metabolism and Pharmacokinetics (DMPK) (in vitro and in vivo), Bioanalysis and Biomarkers, Predictive and Computational Toxicology, Toxicogenomics, Targeted Proteomics, Histology and Pathology, Consultative Drug Discovery Programs, Safety Assessment, Toxicology, Exploratory Toxicology, Genetic Toxicology, Safety Pharmacology, Developmental and Reproductive Toxicology, Carcinogenicity, Pathology, Bioanalysis: Large Molecule (GLP), Bioanalysis: Small Molecule (GLP), Impurities Assessment, Archive, Surgical Support and Medical Device Testing, Research Models and Services, Genetically Engineered Models and Services (GEMS), Full Spectrum Health Monitoring, Custom Antibody Production Services, Biospecimen Services, Contract Breeding Services, Tumor Models and Services, Genetic Testing Services, Surgical Services, Research Model Support Services.
Q3: What industry does Inotiv Solutions operate in?
A3: Inotiv Solutions operates in the pharmaceutical and biotechnology industries, specifically in the field of in vivo discovery and toxicology.
Q4: What is the company's focus on the 3Rs (Reducing, Reusing, Recycling) principle?
A4: The company emphasizes its commitment to the 3Rs principle, which aims to minimize animal use in research. Inotiv collaborates with clients to perform customized studies that meet their unique drug development needs while minimizing the number of study subjects.
Q5: What is the significance of AAALAC-accredited laboratories for Inotiv Solutions?
A5: The company's AAALAC-accredited laboratories are built for purpose and support discovery through GLP regulatory studies using all common research models. This accreditation ensures that Inotiv meets high standards for animal care and welfare.
Q6: What is the company's approach to communication with clients throughout their projects?
A6: Throughout a project, strong lines of communication promote success, with study design, conduct, and data interpretation that exceed client expectations. The company prioritizes open communication to ensure client satisfaction.
Q7: How does Inotiv Solutions support molecules of all classes in its research?
A7: Inotiv Solutions supports molecules of all classes, from small molecules and biologics to gene and cellular therapeutics, providing a comprehensive range of services for lead optimization and candidate selection studies.
Q8: What unique models has the company developed to focus on specific targets of interest?
A8: The company has developed fit-for-purpose, cost-effective, non-routine models of disease, including Diabetes and metabolic disease, Diet-induced hyperlipidemia/atherosclerosis, Inflammation, Pulmonary disease, Sebaceous gland development, Liver-humanized rodent models for hepatic disease, gene delivery, and gene expression studies.
A1: The company name is Integrated Laboratory Systems Inc., but unfortunately, the provided text does not explicitly mention the company's physical address.
Q2: What products and services does Inotiv Solutions offer for in vivo discovery and toxicology?
A2: Inotiv Solutions offers a wide range of products and services, including Discovery and Translational Sciences, Disease Pharmacology (in vitro and in vivo), Drug Metabolism and Pharmacokinetics (DMPK) (in vitro and in vivo), Bioanalysis and Biomarkers, Predictive and Computational Toxicology, Toxicogenomics, Targeted Proteomics, Histology and Pathology, Consultative Drug Discovery Programs, Safety Assessment, Toxicology, Exploratory Toxicology, Genetic Toxicology, Safety Pharmacology, Developmental and Reproductive Toxicology, Carcinogenicity, Pathology, Bioanalysis: Large Molecule (GLP), Bioanalysis: Small Molecule (GLP), Impurities Assessment, Archive, Surgical Support and Medical Device Testing, Research Models and Services, Genetically Engineered Models and Services (GEMS), Full Spectrum Health Monitoring, Custom Antibody Production Services, Biospecimen Services, Contract Breeding Services, Tumor Models and Services, Genetic Testing Services, Surgical Services, Research Model Support Services.
Q3: What industry does Inotiv Solutions operate in?
A3: Inotiv Solutions operates in the pharmaceutical and biotechnology industries, specifically in the field of in vivo discovery and toxicology.
Q4: What is the company's focus on the 3Rs (Reducing, Reusing, Recycling) principle?
A4: The company emphasizes its commitment to the 3Rs principle, which aims to minimize animal use in research. Inotiv collaborates with clients to perform customized studies that meet their unique drug development needs while minimizing the number of study subjects.
Q5: What is the significance of AAALAC-accredited laboratories for Inotiv Solutions?
A5: The company's AAALAC-accredited laboratories are built for purpose and support discovery through GLP regulatory studies using all common research models. This accreditation ensures that Inotiv meets high standards for animal care and welfare.
Q6: What is the company's approach to communication with clients throughout their projects?
A6: Throughout a project, strong lines of communication promote success, with study design, conduct, and data interpretation that exceed client expectations. The company prioritizes open communication to ensure client satisfaction.
Q7: How does Inotiv Solutions support molecules of all classes in its research?
A7: Inotiv Solutions supports molecules of all classes, from small molecules and biologics to gene and cellular therapeutics, providing a comprehensive range of services for lead optimization and candidate selection studies.
Q8: What unique models has the company developed to focus on specific targets of interest?
A8: The company has developed fit-for-purpose, cost-effective, non-routine models of disease, including Diabetes and metabolic disease, Diet-induced hyperlipidemia/atherosclerosis, Inflammation, Pulmonary disease, Sebaceous gland development, Liver-humanized rodent models for hepatic disease, gene delivery, and gene expression studies.
Customs Data
As a purchaser
As a Supplier
Get the Whole details
Contact
Total found ??? Contacts
All
Boss
Management
Procurement
Other
Get the Whole details
